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ABSTRACT
Objective To see if the mortality risk among women who
have used oral contraceptives differs from that of never
users.
Design Prospective cohort study started in 1968 with
mortalitydatasuppliedbyparticipatinggeneralpractitioners,
National Health Service central registries, or both.
Setting 1400 general practices throughout the United
Kingdom.
Participants 46112 women observed for up to 39 years,
resulting in 378006 woman years of observation among
never users of oral contraception and 819175 among
ever users.
Main outcome measures Directly standardised adjusted
relative risks between never and ever users for all cause
and cause specific mortality.
Results 1747 deaths occurred in never users of oral
contraception and 2864 in ever users. Compared with
never users, ever users of oral contraception had a
significantly lower rate of death from any cause (adjusted
relative risk 0.88, 95% confidence interval 0.82 to 0.93).
They also had significantly lower rates of death from all
cancers; large bowel/rectum, uterine body, and ovarian
cancer; main gynaecological cancers combined; all
circulatory disease; ischaemic heart disease; and all
other diseases. They had higher rates of violent deaths.
No association between overall mortality and duration of
oral contraceptive use was observed, although some
disease specific relations were apparent. An increased
relative risk of death from any cause between ever users
and never users was observed in women aged under
45 years who had stopped using oral contraceptives
5-9 years previously but not in those with more distant
use. The estimated absolute reduction in all cause
mortality among ever users of oral contraception was 52
per 100000 woman years.
ConclusionOralcontraceptionwasnotassociatedwithan
increased long term risk of death in this large UK cohort;
indeed, a net benefit was apparent. The balance of risks
and benefits, however, may vary globally, depending on
patterns of oral contraception usageand backgroundrisk
of disease.
INTRODUCTION
The Royal College of General Practitioners’ (RCGP)
Oral Contraception Study is one of the world’s largest
continuinginvestigationsinto thehealtheffectsofcon-
traceptivepills.
1Earlyreportsfromthestudyindicated
an increased risk of death among ever users of these
contraceptives,mainlybecauseofanexcessofvascular
events among older users or those who smoked.
23 A
later report, based on up to 25 years of follow-up, sug-
gested that most of the mortality effects of oral contra-
ceptives occurred in current or recent users, with few
effects persisting beyond 10 years after stopping use.
4
However, the median age of women at follow-up was
only 49 years and relatively few deaths from each type
of cancer had occurred. Prolonged follow-up was
needed to determine how long any risks or benefits
last after oral contraception is stopped. A recent pub-
lication from the study using incident cancer data has
suggested that ever users of oral contraceptives may
have a reduced overall risk of cancer.
5 Whether this
translates into an important mortality benefit, and if
so how it relates to other causes of death, is unknown.
WereportthelatestmortalityfindingsfromtheRCGP
Oral Contraception Study, based on up to 39 years of
follow-up and nearly three times as many deaths as
reported earlier.
4
METHODS
The RCGP Oral Contraception Study started in May
1968 when 1400 general practitioners throughout the
United Kingdom recruited approximately 23000
womenwhowereusingoralcontraceptivesandasimi-
larnumberofwomenwhohadneverusedthismethod
ofbirthcontrol.
1Allthewomenweremarriedorliving
as married, most were white, and their mean age at
recruitment was 29 (SD 6.6) years. Information col-
lected at baseline included parity, smoking habits,
social class (based on husband’s occupation), and rele-
vant medical history. The general practitioners subse-
quentlysupplied,atsixmonthlyintervals,information
about any hormonal preparations prescribed, any
pregnancies and their outcome, all new episodes of
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women still under their observation. Women
remained under general practice follow-up until they
left the area of the recruiting doctor (approximately
56% of total cohort), the doctor left the study (13%),
they obtained their contraceptives from a source
other than the general practitioner (3%), they died
(2%), or the study stopped general practice follow-up
at the end of 1996 (26%).
In the mid 1970s, approximately three quarters of
the original cohort (n=35104) were “flagged” at
National Health Service central registries in Scotland
and England, so that subsequent cancers and deaths
would be reported to the study, even if the woman
was no longer under general practice follow-up. The
remaining24%ofwomencouldnotbeflaggedbecause
they, or their general practitioner, left the study before
flagging took place.
We assembled two datasets, both of which included
data until the end of general practice follow-up on
women who had not been flagged (figure). The full
dataset also included periods of observation up to the
dateofdeathorJune2007(whichevercamefirst)forall
flagged women still in the study when general practice
follow-up ended in 1996, flagged never and ever oral
contraceptive users lost to the study before 1996 who
were aged38 yearsor olderat time of loss,and flagged
ever users lost to the study before 1996 who were
younger than 38 years at the time of loss. Flagged
never users younger than 38 years and lost to general
practicefollow-upbefore1996werecensoredfromthe
time of loss because we did not know whether the
womensubsequentlystartedusingoralcontraceptives.
We assumed that older never users were unlikely to
have done so, as 91% of women in the study who
used oral contraceptives started before the age of 38.
Never users in the full dataset, therefore, were women
known,orassumed,tohaveneverusedoralcontracep-
tives.
The general practice observation subset included
periods of observation, deaths, and other relevant
information obtained while women were under obser-
vation by general practitioners, up to their point of
being lost to general practice follow-up, death, or
December 1996 when general practice follow-up
ended (whichever came first). This subset contained
information about use of hormone replacement ther-
apy while under general practice follow-up, as well as
comprehensive data about the type and duration of
oral contraceptives used.
The deaths were coded using ICD-8 (international
classification of diseases, 8th revision). We grouped
Recruited cohort (n=47 173)
Cohort for analysis (n=46 112)
Women not flagged (n=11 008) Flagged women (n=35 104)
Excluded from analysis (n=1061):
  No GP observation (n=773)
  Information missing for at least one covariate (n=288)
Under GP
observation 
Position at 1996
No of women
Dead
Alive
Total woman
years
Ever
62
6476
171 880
Never
73
3883
115 800
Left age <38 
Ever
74
7687
30 887
Left age ≥38
Ever
476
7161
115 521
Never
387
4671
85 101
Never
23
4131
17 922
Under GP
observation at 1996
Position at 2007
No of women
Dead
Alive
Total woman
years
Ever
640
5898
240 693
Never
478
3478
156 871
Left age <38 
Ever
641
7120
285 558
Left age ≥38
Ever
1531
6106
268 202
Never
1209
3849
185 294
Never
23
4131
17 922
No of women
Dead
Alive
Total woman
years
Ever
18
5364
15 438
Never
13
3021
10 397
Ever
34
1454
9284
Never
24
1080
7522
Left age <38  Left age ≥38
No of women
Dead
Alive
Total woman
years
Ever
664
28 142
343 010
Never
520
16 786
236 742
GP observation subset
No of women
Dead
Alive
Total woman
years
Ever
2864
25 942
819 175
Never
1747
15 559
378 006
Full dataset
Flow chart of RCGP Oral Contraception Study
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rectum (ICD-8 code 153-154), gallbladder and liver
(155-156), lung (162), melanoma (172), breast (174),
invasive cervix (180), uterine body (182), ovary (183),
central nervous system and pituitary (191 and 1943),
site unknown (199), and other cancers (any death
coded between 140 and 209 not already mentioned);
main gynaecological cancers combined (180, 182, and
183); any cancer (140-209); ischaemic heart disease
(410-414), other heart (420-429), cerebrovascular dis-
ease (430-438), other circulatory (any death coded
390-458notalreadymentioned);allcirculatorydisease
combined (390-458); all digestive disease (520-577);
liver disease (570-573); violent deaths (800-999, E800-
999); suicide (E950-959); all other causes (any death
with a code not already mentioned); and any death
(000-999, all E codes). These groupings were broadly
similar to those used in our most recent mortality
report,
4 and we used them for ease of comparison.
Most deaths in the full dataset were notified by the
central registries only (75% (3437/4611) of all deaths).
Of the 1184 deaths in the general practice observation
subset, 160 (14%) were notified by the general practi-
tioner only, 25 (2%) by the central registries only, and
999 (84%) by both sources. If a discrepancy between
sourcesoccurred,wesoughtclarificationfromthegen-
eral practitioner whenever possible. Three deaths
occurred for which the event date differed by more
than three months and 52 for which the discrepancy
in dates was between one and three months. In each
case, we used the information notified by the general
practitioner. For 28 deaths, differences in the ICD-8
codescouldnotbereconciled,soweusedtheinforma-
tion notified by the general practitioner. On 12 occa-
sions, date of death preceded other general practice
observation data, and in these circumstances we
assumed that the woman was still alive and removed
the inconsistent date of death.
Statistical analysis
We used relative risk to measure associations between
use of oral contraceptives and mortality. We aggre-
gated deaths (numerator) and periods of observation
(denominator) according to each woman’s status at
each calendar month while under general practice fol-
low-up or that pertaining when she left such follow-up
(except for age, which continued to change). We
included women recruited as never users who subse-
quentlystartedoralcontraceptioninthepillusergroup
from the date of starting.
We used the dstdize program in Stata 10.1 to calcu-
late unadjusted and directly standardised death rates
among ever users and never users of oral contracep-
tives. We standardised rates for the full dataset for
smoking (0, 1-14, ≥15 cigarettes daily) and social class
(non-manual, manual) at recruitment, parity (0, 1, 2,
≥3) at 1996 or time of death, and age group (<30, 30-
39, 40-49, 50-59, 60-69, ≥70 years) at 2007 or time of
death. When analysing the general practice observa-
tionsubset,weusedthe samevariables(withcollapsed
age categories (<39, 40-49, ≥50) for analyses of the
duration of oral contraceptive use), in addition to use
of hormone replacement therapy during general prac-
tice follow-up (never, ever). As higher mortality in
older women may mask the effects of stopping oral
contraception in younger women in the general prac-
tice observation subset, we examined risk of death by
time since stopping oral contraception among women
aged under 45 years, adjusting for age group (<30, 30-
34,35-39,40-44),parity,socialclass,andsmoking.We
used this cut-off age because few women in the cohort
used hormone replacement therapy before the age of
45. We usedthe totalpopulation(ever users and never
users)availableforeachanalysisasthestandard.Asthe
standard populations and adjusting variables were dif-
ferent in each analysis, the results should not be com-
pared directly.
We assumed approximate normality for the log of
estimated relative risks when calculating 95% confi-
dence intervals.
6 We calculated the log-linear test for
trend for duration of oral contraception use by includ-
ingeachcategoryasametricexplanatoryvariablewith
evenly spaced levels and using the Stata command
stmh. We did not calculate trends for time since last
use, as the data were too sparse for many categories
of death. For clarity of presentation, we have shown
only standardised rates for the analyses of duration of
use and time since last use of oral contraception.
RESULTS
The full dataset contained more than 819000 woman
yearsofobservationforeverusersand378000woman
Table 1 |Characteristics of women in ever used and never used oral contraceptive groups.
Values are numbers (percentages) unless stated otherwise
Characteristic
Never users
(n=17 306)
Ever users
(n=28 806) P value
Age at recruitment (years):
<30 8922 (51.6) 18 323 (63.6)
<0.001
30-39 6605 (38.2) 8712 (30.2)
40-49 1747 (10.1) 1748 (6.1)
50-59 32 (0.2) 23 (0.1)
Smoking at recruitment (cigarettes/day):
0 10 437 (60.3) 15 081 (52.4)
<0.001 1-14 4188 (24.2) 7994 (27.7)
≥15 2681 (15.5) 5731 (19.9)
Parity at recruitment:
0 3490 (20.2) 4871 (16.9)
<0.001
1 4497 (26.0) 6577 (22.8)
2 5495 (31.7) 9193 (31.9)
≥3 3824 (22.1) 8165 (28.3)
Social class at recruitment:
Non-manual 6680 (38.6) 10 364 (36.0)
<0.001
Manual 10 626 (61.4) 18 442 (64.0)
Use of hormone replacement therapy
during general practice follow-up:
Never 15 559 (89.9) 25 038 (86.9)
<0.001
Ever 1747 (10.1) 3768 (13.1)
Figures based on full dataset for age, smoking, parity, and social class, and on general practice observation
subset for hormone replacement therapy use.
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the general practice observation subset were 343000
and 237000 woman years. Compared with never
users, ever users tended to be younger, smokers, and
of higher parity and manual social class at recruitment
and to have used hormone replacement therapy while
under general practice observation (table 1).
In the full dataset, all cause mortality among ever
users of oral contraception was 12% lower than that
of never users (adjusted relative risk 0.88, 95% confi-
dence interval 0.82 to 0.93) (table 2). We found signif-
icantly lower rates among ever users of deaths from all
cancers; cancer of the large bowel/rectum, uterine
body, or ovaries; main gynaecological cancers com-
bined; all circulatory disease; ischaemic heart disease;
and all other diseases. The all other diseases category
included 445 respiratory conditions, 72 nervous sys-
tem and sense organ conditions, 68 infective and para-
siticdisorders,55symptomsandilldefinedconditions,
51 mental disorders, 47 genitourinary disorders, and
41 endocrine and metabolic disorders. Ever users of
oral contraceptives also had a significantly higher rate
of violent death.
All cause mortality increased with age and smoking
in both ever users and never users of oral contracep-
tives (table 3). In the youngest (<30 years) age group,
ever users of oral contraceptives had an almost three-
fold greater rate of any death than did never users
(adjusted relative risk 2.85, 1.17 to 6.94). From the
age of 50, however, the rate of any death among ever
users of oral contraceptives was significantly lower
than that in never users. In all categories of smoking,
socialclass,andparity,everusersoforalcontraception
had lower all cause mortality than did never users,
although not all of the relative risk estimates were sta-
tistically significant.
The pattern of relative risks was different when we
used the smaller general practice observation subset
(table 4). In this subset, the adjusted relative risk for
anydeathbetweeneverusersandneveruserswasvery
close to unity (0.98, 0.88 to 1.10). Compared with
never users, ever users had a significantly lower rate
of death from ovarian cancer, main gynaecological
cancers combined, and all other diseases and a higher
rate of death from all circulatory disease, cerebro-
vascular disease, other circulatory disease, and vio-
lence.
Themediandurationoforalcontraceptiveuseinthe
study was 44 (range 1-344, interquartile range 19-83)
months. We found no consistent pattern of materially
different all cause mortality among women who had
used oral contraception for different durations, when
Table 2 |Risk of death among ever and never users of oral contraceptives in full dataset
Cause of death ICD-8 codes
Never users Ever users
Adjusted relative
risk† (95% CI)
Observed rate
(No)
Standardised
rate*
Observed rate
(No)
Standardised
rate*
All causes 000-999, all E codes 462.16 (1747) 417.45 349.62 (2864) 365.51 0.88(0.82to0.93)
All cancers 140-209 205.29 (776) 194.55 160.16 (1312) 165.45 0.85(0.78to0.93)
Large bowel and rectum 153-154 21.16 (80) 20.05 11.84 (97) 12.41 0.62(0.46to0.83)
Gallbladder/liver 155-156 3.17 (12) 3.12 1.83 (15) 2.03 0.65(0.30to1.39)
Lung 162 26.45 (100) 26.08 31.49 (258) 31.70 1.22(0.96to1.53)
Melanoma 172 2.65 (10) 2.67 1.95 (16) 1.95 0.73(0.33to1.61)
Breast 174 44.44 (168) 43.91 38.09 (312) 39.41 0.90(0.74to1.08)
Invasive cervix 180 3.70 (14) 4.02 5.62 (46) 5.38 1.34(0.74to2.44)
Uterine body 182 5.03 (19) 4.47 1.59 (13) 1.94 0.43(0.21to0.88)
Ovary 183 19.84 (75) 18.04 9.16 (75) 9.47 0.53(0.38to0.72)
Main gynaecological 180, 182, 183 28.57 (108) 26.51 16.36 (134) 16.80 0.63(0.49to0.82)
CNS-pituitary 191, 1943 5.03 (19) 4.47 3.42 (28) 3.74 0.84(0.47to1.50)
Site unknown 199 22.22 (84) 20.50 17.21 (141) 18.02 0.88(0.67to1.15)
Other cancers 140-209, except above 51.59 (195) 47.19 37.96 (311) 39.39 0.83(0.70to1.00)
All circulatory diseases 390-458 132.54 (501) 115.18 93.14 (763) 99.15 0.86(0.77to0.96)
Ischaemic heart disease 410-414 64.02 (242) 57.41 41.02 (336) 42.85 0.75(0.63to0.88)
Other heart 420-429 15.34 (58) 11.90 9.03 (74) 10.12 0.85(0.60to1.20)
Cerebrovascular disease 430-438 32.54 (123) 27.86 27.71(227) 29.19 1.05(0.84to1.30)
Other circulatory 390-409, 440-458 20.63 (78) 18.02 15.38 (126) 16.98 0.94(0.71to1.25)
All digestive disease 520-577 18.25 (69) 16.53 15.38 (126) 15.67 0.95(0.71to1.27)
Liver disease 570-573 5.56 (21) 5.48 7.20 (59) 7.20 1.32(0.80to2.16)
Violence 800-999, E800-999 13.49 (51) 12.86 19.04 (156) 19.20 1.49(1.09to2.05)
Suicide E950-959 4.50 (17) 4.79 6.10 (50) 6.03 1.26(0.73to2.18)
All other diseases All codes, except above 92.06 (348) 77.80 61.4 (503) 65.59 0.84(0.74to0.97)
CNS=central nervous system; ICD-8=international classification of diseases, version 8.
*Standardised rate per 100 000 woman years, adjusted for age, parity, smoking, and social class.
†Baseline=never users.
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of decreasing rates of death from large bowel/rectum,
uterinebody, andovariancancersand increasing rates
of other circulatory disease and violent deaths among
women who used oral contraception for longer dura-
tions.
Table 6 shows the rates of death by time since last
use of oral contraception in women aged under 45 in
the general practice observation subset. The rate of
death from any cause among current and recent users
(<5 years since last use) was similar to that of never
users (adjusted relative risk 1.08, 0.83 to 1.40). Thus,
althoughcurrentandrecentusershadastatisticallysig-
nificant doubling of the rate of circulatory death, this
was offset by reductions in the rate of death from non-
circulatory causes. The increased rate of death from
circulatory disease persisted in pill users five to nine
years after stopping use and was accompanied by an
increased rate of death from all cancers combined,
including breastcancer. This resulted in a significantly
increasedadjustedrelativeriskofdeathfromanycause
among this group (1.76, 1.27 to 2.45), compared with
never users. Among women who had stopped taking
the pill more than 10 years previously, the overall
adjusted relative risk of death from any cause was
very close to unity (0.97, 0.61 to 1.53).
DISCUSSION
Continued follow-up of this large UK cohort did not
reveal a substantially increased overall rate of death
among oral contraceptive users, compared with
never users. If anything, the analysis of the full dataset
suggested an overall reduction in mortality, resulting
from lower rates of different specific causes of death,
includingcancerandcirculatorydisease.Ahigherrate
of violent or accidental death among oral contracep-
tive users than among never users has been noted in
the cohort before and seems to be persisting.
1-3
Strengths and limitations of study
Amajorstrengthofthe studywasthe abilitytoinclude
morethanamillionwomanyearsofobservation,accu-
mulated over a 39 year period and involving nearly
three times as many deaths (a total of more than
4600) as before.
4 A previous study has shown good
agreement between the cause of death reported by
the general practitioners and that on the death
certificate.
7 Although both sources of information are
prone to error in the attribution of underlying cause of
death, we have no reason to suspect systematic differ-
encesbecause ofa woman’s use (ornot) oforal contra-
ception.Thisisespeciallysoformorerecentevents,for
which most of the doctors certifying the deaths will
have been unaware of the contraceptive history of the
deceased woman.
We were able to adjust for the potentially important
confounding factors of age, smoking, social class, par-
ity, and (for some analyses of the general practice
observation subset) use of hormone replacement ther-
apy. The adjustments tended to make little difference
to the rates. Smoking data have not been routinely
updatedduringthe study.Useofsmokinginformation
collected at study entry will tend to underestimate the
effects of smoking. This is because women in the
cohort are more likely to have stopped smoking than
started since recruitment, so disproportionately more
womenwillbemisclassifiedinthesmokergroupwitha
decreased risk of smoking related death than in the
non-smoker group at increased risk of such an event.
Furthermore, a study of a subgroup of approximately
10000 women who completed a health survey in the
mid-1990s produced virtually identical estimates of
riskformyocardialinfarctionassociatedwithoralcon-
traceptiveusebasedonupdatedsmokingdata tothose
based on information collected at recruitment.
8 As we
were unable to adjust our results for other lifestyle or
familial variables, residual confounding must remain
an alternative explanation for our findings.
The study has been prone to large losses to follow-
up; the full dataset contains approximately two thirds
of an estimated 1800000 woman years of observation
that would have occurred if nobody had been lost to
follow-up. Biased results could have occurred if a rela-
tion existed between leaving the study, use of the con-
traceptive pill, and risk of death. A previous analysis
has shown that women lost to general practice follow-
up had similar risks of death to those still under
observation,
9 suggesting no major systematic bias
from loss to follow-up. To investigate whether our
results for the full dataset were affected by the censor-
ing of flagged never users younger than 38 years when
losttogeneralpracticefollow-upbefore1996,wedida
sensitivity analysis in which we excluded both flagged
Table 3 |Risk of all cause mortality among ever and never users of different age, parity,
smoking, and social class in full dataset
Variable
Standardised rate* (No) Adjusted relative risk†
(95% CI) Never users Ever users
Age (years):
<30 11.04 (6) 31.44 (25) 2.85 (1.17 to 6.94)
30-39 69.21 (50) 73.21 (133) 1.06 (0.76 to 1.46)
40-49 183.74 (159) 170.17 (368) 0.93 (0.77 to 1.12)
50-59 469.33 (393) 382.88 (812) 0.82 (0.72 to 0.92)
60-69 916.23 (569) 794.48 (916) 0.87 (0.78 to 0.96)
70+ 2461.20 (570) 2153.44 (610) 0.87 (0.78 to 0.98)
Smoking (No of cigarettes/day):
0 307.03 (798) 248.09 (1021) 0.81 (0.74 to 0.89)
1-14 448.95 (474) 408.00 (842) 0.91 (0.81 to 1.02)
≥15 718.23 (475) 664.48 (1001) 0.93 (0.83 to 1.03)
Social class:
Non-manual 357.82 (570) 325.20 (929) 0.91 (0.82 to 1.01)
Manual 453.08 (1177) 386.59 (1935) 0.85 (0.79 to 0.92)
Parity:
0 502.18 (177) 362.13 (146) 0.72 (0.58 to 0.90)
1 416.53 (291) 366.10 (347) 0.88 (0.75 to 1.03)
2 378.89 (572) 334.08 (946) 0.88 (0.79 to 0.98)
≥3 439.05 (707) 388.33 (1425) 0.88 (0.81 to 0.97)
*Standardised rate per 100 000 woman years, adjusted for age, parity, smoking, and social class, except where
variable itself is being examined.
†Baseline=never users.
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teria. The adjusted relative risk for any death was 0.91
(95% confidence interval 0.86 to 0.97). The pattern of
relative risks for specific causes of death also tended to
be very similar to that of the full dataset.
Theanalysesmayhavebeenpronetomisclassification
of exposure, as we assumed that never users older than
38yearswholeftthestudydidnotsubsequentlystartoral
contraception. The level of misclassification is likely to
have been small, and its effect will have been to under-
estimate the oral contraception related risk of death.
Recent experience of the strikingly different results
between observational and randomised experimental
data on the cardiovascular effects of hormone replace-
ment therapy provides a powerful reminder of the
need for care when interpreting observational epide-
miological data.
10 In addition to residual confounding,
healthy survivorship is another possible explanation
for the observed overall reduced risk of death among
ever users. Our cohort is certainly healthier than the
national average—in 1999 the standardised mortality
ratiowas79,
4mainlybecausewomenwithchronicdis-
ease were not recruited to the study.
1 For this to have
contributed to our results, differential survivorship
would have had to occur between women using and
not using oral contraceptives. Although speculating
about how such an effect might have occurred is inter-
esting (for example, through a beneficial effect of reg-
ular blood pressure and other monitoring during and
possibly after use of oral contraception), a clear
mechanism is not apparent, especially one that would
affect different outcomes, including cancer and circu-
latory disease.
We did not examine whether risk of death differed
accordingtothehormonalcontentofthecontraceptive
pills used. Most (75%) of the pills used in the study
contained 50 μg of oestrogen (>50 μg products 12%,
<50 μg formulations 10%, progestogen only prepara-
tions 3%). Most women used preparations from more
thanonecategoryofoestrogendose,almostentirelyin
a downwards direction—for example, from a >50 μg
preparation to a 50 μg preparation. Lack of exclusive
use of any particular dose category means that we can-
not know whetherany associationsbetween deathand
oestrogen dosage are due to the effects of the prepara-
tion used most recently before death or lingering
effects from a previously used (usually higher dose)
formulation.
Comparison with other studies
Two other large, long term cohort studies have found
no significant overall increased risk of death among
Table 4 |Risk of death among ever and never users of oral contraceptives in general practice observation subset
Cause of death ICD-8 code
Never users Ever users
Adjusted relative
risk† (95% CI)
Observed rate
(No)
Standardised
rate*
Observed rate
(No)
Standardised
rate*
All causes 000-999, all E codes 219.65 (520) 206.51 193.58 (664) 203.20 0.98 (0.88 to 1.10)
All cancers 140-209 120.38(285) 116.71 95.91 (329) 103.26 0.88 (0.75 to 1.04)
Large bowel and rectum 153-154 12.25 (29) 11.83 7.00 (24) 8.28 0.70 (0.41 to 1.20)
Gallbladder/liver 155-156 1.69 (4) 1.52 1.46 (5) 2.13 1.40 (0.38 to 5.21)
Lung 162 13.52 (32) 15.54 15.16 (52) 16.30 1.05 (0.67 to 1.63)
Melanoma 172 2.53 (6) 2.32 2.04 (7) 1.98 0.85 (0.29 to 2.54)
Breast 174 35.48 (84) 34.38 30.32 (104) 32.36 0.94 (0.71 to 1.25)
Invasive cervix 180 3.38 (8) 3.63 5.54 (19) 5.54 1.52 (0.67 to 3.48)
Uterine body 182 2.53 (6) 2.11 0.29 (1) 0.26 0.12 (0.01 to 1.03)
Ovary 183 12.25 (29) 11.11 4.08 (14) 4.78 0.43 (0.23 to 0.81)
Main gynaecological 180, 182, 183 18.16 (43) 16.85 9.91 (34) 10.58 0.63 (0.40 to 0.98)
CNS-pituitary 191, 1943 0.84 (2) 0.72 2.62 (9) 2.54 3.53(0.76to16.35)
Site unknown 199 8.45 (20) 7.56 3.50 (12) 3.79 0.50 (0.25 to 1.03)
Other cancers 140-209,exceptabove 27.46 (65) 25.98 23.91 (82) 25.30 0.97 (0.70 to 1.35)
All circulatory disease 390-458 42.24 (100) 37.76 51.02 (175) 51.83 1.37 (1.07 to 1.75)
Ischaemic heart disease 410-414 21.12 (50) 19.43 18.37 (63) 19.56 1.01 (0.69 to 1.46)
Other heart 420-429 3.38 (8) 2.66 4.37 (15) 4.84 1.82 (0.77 to 4.29)
Cerebrovasculardisease 430-438 13.94 (33) 12.50 19.82 (68) 18.89 1.51 (1.00 to 2.29)
Other circulatory 390-409, 440-458 3.80 (9) 3.17 8.45 (29) 8.54 2.70 (1.28 to 5.70)
All digestive disease 520-577 9.29 (22) 7.65 6.41 (22) 6.50 0.85 (0.47 to 1.54)
Liver disease 570-573 4.22 (10) 3.63 3.79 (13) 3.99 1.10 (0.48 to 2.51)
Violence 800-999, E800-999 10.98 (26) 10.64 19.82 (68) 20.41 1.92 (1.22 to 3.01)
Suicide E950-959 5.49 (13) 5.66 8.45 (29) 8.80 1.56 (0.81 to 2.99)
All other diseases All codes, except
above
35.90 (85) 32.78 19.53 (67) 20.41 0.62 (0.45 to 0.86)
CNS=central nervous system; ICD-8=international classification of diseases, version 8.
*Standardised rate per 100 000 woman years, adjusted for age, parity, smoking, social class, and use of hormone replacement therapy.
†Baseline=never users.
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1112 The North American Nurses’
Health Study reported results relating to 2879 deaths
occurring during 1.3 million woman years of observa-
tion accumulated between 1976 and 1988 (adjusted
relative risk in ever users 0.93, 0.85 to 1.10).
11 Most
oral contraceptive users in the Nurses Health Study
were past users, so its results are most comparable
with our full dataset results. The adjusted relative
risks for deaths due to cancer (0.92, 0.81 to 1.03) and
cardiovascular disease (0.86, 0.71 to 1.05) were also
very similar to the results of our full dataset. This is
reassuring given that the background risk of disease,
and the associated physical, psychosocial, and cultural
riskfactors,differbetweenwomenlivingoneitherside
of the Atlantic.
ResultsfromthesmallerUKOxfordFamilyPlanning
Association Contraception Study, based on 889 deaths
recorded during nearly 0.5 million woman years of
observation between 1968 and 2000, were also very
similartotheresultsofourfulldataset(adjustedrelative
risk in ever users 0.89, 0.77 to 1.02).
12 Although our
findings for cause specific deaths are broadly in line
with the Oxford study, we found a lower risk of death
from cervical cancer among ever users.
Weareunabletoexplaintheincreasedriskofviolent
andaccidentaldeathsinourstudyamongeverusersof
oral contraceptives. The persistence of this effect is
noteworthy. The Nurses Health Study and the Oxford
studydidnotfindasignificantlyincreasedriskofdeath
from suicide and trauma or from accidents and
violence.
1112
As all of the cohorts have aged, the proportion of
periodsofobservationamongeverusersduetocurrent
and recent use has decreased, thereby diminishing the
contribution that short term risks among current and
recent users make to the overall risk within ever users.
Over time, the overall relative risk of death in the
RCGP study has diminished from 1.4 in 1977 to 1.0 in
1999,
24andthento0.88inthefulldatasetinthisreport.
These observations provide an important reminder
that perceptions about the safety of oral contraception
will be heavily influenced by whether current, recent,
or more distant use is being assessed.
Conclusions and policy implications
Our results do not suggest a persisting or emerging
mortality risk over time among women who have
used oral contraceptives. The reduced rate of cancer
seen among the cohort when incident data were used
Table 5 |Risk of death by duration of oral contraceptive use in general practice observation subset
Cause of death
Rate (No)
in never users
Duration of oral contraceptive use
<4 years 4-8 years ≥8 years
Rate* (No) ARR† (95% CI) Rate* (No) ARR† (95% CI) Rate* (No) ARR† (95% CI)
All causes 210.10 (520) 191.98 (247) 0.91 (0.79 to 1.06) 215.66 (220) 1.03 (0.88 to 1.20) 211.00 (197) 1.00 (0.85 to 1.18)
All cancers 117.98 (285) 103.99 (126) 0.88 (0.71 to 1.09) 92.66 (96) 0.79 (0.62 to 0.99) 113.44 (107) 0.96 (0.77 to 1.20)
Large bowel and rectum 11.83 (29) 12.07 (12) 1.02 (0.52 to 2.00) 7.71 (8) 0.65 (0.30 to 1.43) 5.34 (4) 0.45 (0.16 to 1.28)
Gallbladder/liver 1.48 (4) 2.45 (2) 1.66 (0.30 to 9.04) 1.17 (1) 0.79 (0.09 to 7.08) 2.33 (2) 1.57 (0.29 to 8.59)
Lung 15.21 (32) 17.14 (20) 1.13 (0.64 to 1.97) 9.95 (11) 0.65 (0.33 to 1.30) 17.79 (21) 1.17 (0.67 to 2.03)
Melanoma 2.32 (6) 2.81 (4) 1.21 (0.34 to 4.28) 0.78 (1) 0.34 (0.04 to 2.79) 1.64 (2) 0.71 (0.14 to 3.50)
Breast 34.59 (84) 31.96 (41) 0.92 (0.64 to 1.34) 30.04 (31) 0.87 (0.58 to 1.31) 39.13 (32) 1.13 (0.75 to 1.70)
Invasive cervix 3.59 (8) 3.88 (5) 1.08 (0.35 to 3.31) 5.75 (6) 1.60 (0.56 to 4.62) 10.67 (8) 2.97 (1.12 to 7.92)
Uterine body 2. 15 (6) 0.90 (1) 0.42 (0.05 to 3.45) – (0) –– (0) –
Ovary 11.53 (29) 5.20 (7) 0.45 (0.20 to 1.03) 2.73 (3) 0.24 (0.07 to 0.78) 3.97 (4) 0.34 (0.12 to 0.98)
Main gynaecological 17.32 (43) 9.98 (13) 0.58 (0.31 to 1.07) 8.49 (9) 0.49 (0.24 to 1.01) 14.78 (12) 0.85 (0.45 to 1.62)
CNS-pituitary 0.68 (2) 0.66 (1) 0.97 (0.09 to 10.72) 4.58 (5) 6.78 (1.32 to 34.96) 2.19 (3) 3.24 (0.54 to 19.39)
Site unknown 7.77 (20) 4.84 (6) 0.62 (0.25 to 1.55) – (0) – 5.88 (6) 0.76 (0.30 to 1.89)
Other cancers 26.78 (65) 22.04 (27) 0.82 (0.53 to 1.29) 29.85 (30) 1.11 (0.72 to 1.72) 24.49 (25) 0.91 (0.58 to 1.45)
All circulatory disease 39.37 (100) 47.13 (61) 1.20 (0.87 to 1.65) 71.89 (71) 1.83 (1.35 to 2.48) 42.69 (43) 1.08 (0.76 to 1.55)
Ischaemic heart disease 19.94 (50) 19.65 (22) 0.99 (0.60 to 1.63) 33.85 (32) 1.70 (1.09 to 2.65) 7.94 (9) 0.40 (0.20 to 0.81)
Other heart 3.34 (8) 4.12 (5) 1.24 (0.40 to 3.78) 8.00 (6) 2.40 (0.83 to 6.91) 4.65 (4) 1.39 (0.42 to 4.63)
Cerebrovascular disease 12.67 (33) 16.19 (22) 1.28 (0.74 to 2.19) 22.82 (26) 1.80 (1.08 to 3.01) 20.11 (20) 1.59 (0.91 to 2.77)
Other circulatory 3.42 (9) 7.17 (12) 2.09 (0.88 to 4.97) 7.22 (7) 2.11 (0.79 to 5.66) 9.99 (10) 2.92 (1.19 to 7.18)
All digestive disease 7.73 (22) 4.30 (6) 0.56 (0.23 to 1.37) 7.80 (9) 1.01 (0.46 to 2.19) 6.57 (7) 0.85 (0.36 to 1.99)
Liver disease 3.59 (10) 2.99 (4) 0.83 (0.26 to 2.65) 2.83 (3) 0.79 (0.22 to 2.86) 5.88 (6) 1.64 (0.60 to 4.51)
Violence 10.6 (26) 20.61 (32) 1.94 (1.16 to 3.26) 20.39 (21) 1.92 (1.08 to 3.42) 22.85 (15) 2.16 (1.14 to 4.07)
Suicide 5.62 (13) 7.88 (12) 1.40 (0.64 to 3.08) 11.02 (12) 1.96 (0.90 to 4.30) 12.04 (5) 2.14 (0.76 to 6.01)
All other diseases 33.45 (85) 15.47 (21) 0.46 (0.29 to 0.75) 21.85 (22) 0.65 (0.41 to 1.04) 24.77 (24) 0.74 (0.47 to 1.16)
ARR=adjusted relative risk; CNS=central nervous system.
*Standardised rate per 100 000 woman years, adjusted for age, parity, smoking, social class, and use of hormone replacement therapy.
†Adjusted relative risk with never users as baseline.
Tests for trend were all non-significant (P>0.05), except for cancer of large bowel/rectum (P=0.039), uterine body (P=0.039), and ovary (P=0.005), other circulatory disease (P=0.024), and
violent deaths (P=0.026).
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cancer, principally through long term reductions in
large bowel/rectum, uterine body, and ovarian
cancers.
5 Many women, especially those who used the
first generation of oral contraceptives many years ago,
are likely to be reassured by our results. However, our
findings might not reflect the experience of women
using oral contraceptives today, if currently available
preparations have a different risk than earlier products
orifdifferencesinpatternsofusage(suchasageatstart-
ing or duration of use) materially affect mortality risk.
From the full dataset, the estimated overall absolute
reductioninmortalityamongeverusersoforalcontra-
ception was 52 per 100000 woman years, with larger
benefits in older women outweighing more modest
excess risks among younger women (20 more deaths
per 100000 woman years at age <30, 4 more deaths
per 100000 at age 30-39, 14 fewer deaths per 100000
at age 40-49, 86 fewer deaths per 100000 at age 50-59,
122 fewer deaths per 100000 at age 60-69, and 308
fewer deaths per 100000 at age ≥70). Although the
proportion of increases or decreases in mortality
directly attributable to oral contraception cannot be
determined, these figures indicate that, at least in this
relatively healthy UK cohort, oral contraceptionis not
significantly associated with a major public health
problem. The level of reduction in mortality seen in
different parts of the world will depend on factors
such as levels of oral contraception usage, duration of
use, age at stopping, and the prevalence of disease.
Table 6 |Risk of death by time since last oral contraceptive use in women aged <45 years in general practice observation subset
Rate* (No)
in never users
Time since last oral contraceptive use
Current and <5 years 5-9 years ≥10 years
Rate* (No) ARR† (95% CI) Rate* (No) ARR† (95% CI) Rate* (No) ARR† (95% CI)
All causes 69.80 (103) 75.49 (124) 1.08 (0.83 to 1.40) 123.0 (53) 1.76 (1.27 to 2.45) 67.40 (22) 0.97 (0.61 to 1.53)
All cancers 36.11 (52) 29.66 (43) 0.82 (0.55 to 1.23) 68.86(25) 1.91 (1.18 to 3.07) 14.13 (6) 0.39 (0.17 to 0.91)
Large bowel and rectum 3.75 (5) 2.13 (3) 0.57 (0.14 to 2.37) – (0) – 4.89 (1) 1.30 (0.15 to 11.16)
Gallbladder/liver – (0) – (0) – 3.53 (1) –– (0) –
Lung 3.15 (4) 3.25 (4) 1.03 (0.26 to 4.12) 3.24 (2) 1.03 (0.19 to 5.61) – (0) –
Melanoma 1.41 (2) 1.23 (2) 0.88 (0.12 to 6.21) – (0) –– (0) –
Breast 10.72 (16) 11.92 (17) 1.11 (0.56 to 2.20) 32.08 (12) 2.99 (1.42 to 6.33) 1.63 (1) 0.15 (0.02 to 1.15)
Invasive cervix 1.67 (2) 3.13 (5) 1.87 (0.36 to 9.65) 8.24 (3) 4.92 (0.82 to 29.44) 3.26 (2) 1.95 (0.27 to 13.83)
Uterine body – (0) – (0) –– (0) –– (0) –
Ovary 3.08 (5) 1.01 (1) 0.33 (0.04 to 2.80) 5.30 (2) 1.72 (0.33 to 8.86) 1.63 (1) 0.53 (0.06 to 4.53)
Main gynaecological 4.76 (7) 4.20 (6) 0.88 (0.30 to 2.63) 13.54 (5) 2.85 (0.90 to 8.97) 4.89 (3) 1.03 (0.27 to 3.98)
CNS-pituitary – (0) – (0) – 1.77 (1) –– (0) –
Site unknown – (0) – (0) –– (0) –– (0) –
Other cancers 12.33 (18) 7.00 (11) 0.57 (0.27 to 1.20) 14.71 (4) 1.19 (0.40 to 3.53) 2.72 (1) 0.22 (0.03 to 1.65)
All circulatory disease 9.18 (14) 18.69 (31) 2.04 (1.08 to 3.83) 28.25 (15) 3.08 (1.49 to 6.38) 21.20 (8) 2.31 (0.97 to 5.51)
Ischaemic heart disease 3.89 (5) 5.43 (7) 1.40 (0.44 to 4.40) 3.24 (2) 0.83 (0.16 to 4.29) – (0) –
Other heart 0.40 (1) 1.73 (3) 4.32 (0.45 to 41.49) – (0) –– (0) –
Cerebrovascular disease 4.89 (8) 7.83 (14) 1.60 (0.67 to 3.82) 18.24 (10) 3.73 (1.47 to 9.45) 5.98 (5) 1.22 (0.40 to 3.74)
Other circulatory – (0) 3.69 (7) – 7.06 (3) – 15.22 (3) –
All digestive disease 2.08 (4) 3.64 (6) 1.75 (0.49 to 6.21) 5.89 (3) 2.83 (0.63 to 12.66) – (0) –
Liver disease 1.67 (3) 2.46 (3) 1.47 (0.30 to 7.28) 5.89 (3) 3.51 (0.71 to 17.41) – (0) –
Violence 10.38 (15) 14.55 (28) 1.40 (0.75 to 2.62) 12.36 (6) 1.19 (0.46 to 3.07) 16.85 (3) 1.62 (0.47 to 5.61)
Suicide 5.49 (7) 7.39 (14) 1.34 (0.54 to 3.33) 7.36 (3) 1.34 (0.35 to 5.18) 5.44 (1) 0.99 (0.12 to 8.04)
All other diseases 11.39 (17) 8.95 (16) 0.79 (0.40 to 1.56) 7.65 (4) 0.67 (0.23 to 2.00) 14.68 (5) 1.29 (0.48 to 3.49)
ARR=adjusted relative risk; CNS=central nervous system.
*Standardised rate per 100 000 woman years, adjusted for age (<30, 30-34, 35-39, 40-44 years), parity, smoking, and social class.
†Adjusted relative risk with never users as baseline.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Most of the mortality risks associated with oral
contraception seem to disappear within about 10 years of
stopping
Ever users of oral contraception have a reduced overall risk
of incident cancer, but whether this translates into an
important mortality benefit is not known
WHAT THIS STUDY ADDS
Perceptions about the safety of oral contraception depend
on whether current, recent, or more distant use of oral
contraception is being assessed
Oral contraception was not associated with an increased
long term risk of death in this UK cohort and may even
produce a net benefit (absolute risk reduction among ever
users 52 per 100000 woman years)
Thebalanceofrisksandbenefits,however,mayvaryaround
the world, depending on patterns of oral contraception
usage and the prevalence of different diseases
RESEARCH
page 8 of 9 BMJ | ONLINE FIRST | bmj.comThispaperwouldnothavebeenpossiblewithouttheleadershipofClifford
Kay, who established and ran the study for its first 26 years, or the many
generalpractitionerswhocontributeddata.WealsothankAileenMurphyfor
databaseadministrationsupportandSivasubramaniamSelvarajwhowrote
most of the programming in Stata.
Contributors: PCH had the original idea, advised on and checked the
analyses, and wrote the first and subsequent drafts of the paper. LI and
AME had responsibility for updating the database with information on
deaths. LI and VA checked the data extractions and analyses. TM was
responsible for data analysis. AJL, with AME, checked the validity of the
programusedtoanalysethedata.VAmaintainedthestudydatabaseand
extracted data for analysis. All authors contributed to the scientific
development of the paper, commented on successive drafts, and agreed
to the final manuscript. PCH is the guarantor.
Funding: The study received funding from the Royal College of General
Practitioners, Medical Research Council, Imperial Cancer Research Fund,
British Heart Foundation, Cruden Foundation, Schering AG, Schering
Health Care, Wyeth Ayerst International, Ortho Cilag, and Searle. None of
the funders had a role in the data collection, analysis, or interpretation or
in the writing of this paper.
Competing interests: The Centre of Academic Primary Care has received
payments from Schering Plough and Wyeth Pharmaceutical for lectures
and advisory board work provided by PCH.
Ethical approval: The study was established before the introduction of
research ethics committees in the UK. Even so, procedures were used to
maintain the confidentiality of women. Correspondence between
participating doctors and the study, and between the NHS central
registries and the study, used a unique study number, the key to which
only the general practitioners knew.
Data sharing: No additional data available.
1 Royal College of General Practitioners. Oral contraceptives and
health. Pitman Medical, 1974.
2 Royal College of General Practitioners’ Oral Contraception Study.
Mortality among oral contraceptive users. Lancet 1977;ii:727-31.
3 Royal College of General Practitioners’ Oral Contraception Study.
Further analyses of mortality in oral contraceptive users. Lancet
1981;i:541-6.
4 Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality
associatedwithoralcontraceptives:25yearfollowupofcohortof46
000 women from the Royal College of General Practitioners’ Oral
Contraception Study. BMJ 1999;318:96-100.
5 H a n n a f o r dP C ,S e l v a r a jS ,E l l i o t tA M ,A n g u sV ,I v e r s e nL ,L e eA J .
Cancer risk among oral contraceptive users: cohort data from the
RoyalCollegeofGeneralPractitioner’sOralContraceptionStudy.BMJ
2007;335:651.
6 Rosner B. Fundamentals of biostatistics. Duxbury Press, 2000.
7 Wingrave SJ, Beral V, Adelstein AM, Kay CR. Comparison of cause of
deathcodingondeathcertificateswithcodingintheRoyalCollegeof
General Practitioners’ Oral Contraception Study. JE p i d e m i o l
Community Health 1981;35:51-8.
8 Owen-Smith V, Hannaford PC, Warskyj M, Ferry S, Kay CR. Effects of
changes in smoking status on risk estimates for myocardial
infarction among women recruited for the Royal College of General
Practitioners’ Oral Contraception Study in the UK. JE p i d e m i o l
Community Health 1998;52:420-4.
9 BeralV,HermonC,KayC,HannafordPC,DarbyS,ReevesG.Mortality
in relation to method of follow-up in the Royal College of General
Practitioners’ Oral Contraception Study. In: Hannaford PC, Webb
AMC, eds. Evidence-guided prescribing of the pill. Parthenon
Publishing Group, 1996:327-39.
1 0 P r e n t i c eR L ,L a n g e rR ,S t e f a n i c kM L ,H o w a r dB V ,H e t t i n g e rM ,
AndersonG,etal.Combinedpostmenopausalhormonetherapyand
cardiovascular disease: toward resolving the discrepancy between
observational studies and the Women’s Health Initiative Clinical
Trial. Am J Epidemiol 2005;162:404-14.
11 Colditz GA. Oral contraceptive use and mortality during 12 years of
follow-up: the Nurses’ Health Study. A n nI n t e r nM e d
1994;120:821-6.
12 Vessey M, Painter R, Yeates D. Mortality in relation to oral
contraceptive use and cigarette smoking. Lancet 2003;362:185-91.
Accepted: 5 January 2010
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 9 of 9